USFDA issues Form 483 with 4 observations to Biocon

A Form 483 is an official document used by the USFDA to communicate its observations of potential violations during a GMP inspection.

191
USFDA Inspection audit Form 483
USFDA Form 483

Last Updated on July 6, 2024 by The Health Master

Form 483

Biotechnology leader Biocon Ltd. announced that the U.S. Food and Drug Administration (USFDA) conducted a Good Manufacturing Practice (GMP) inspection of their Active Pharmaceutical Ingredient (API) facility (Site 5) located in Visakhapatnam, Andhra Pradesh, concluding on June 21, 2024 and issued Form 483.

Four Observations Noted by USFDA

Following the inspection, the USFDA issued a Form 483 to Biocon, outlining four observations.

These observations detail potential non-compliance issues that could impact the facility’s adherence to the Food, Drug, and Cosmetic (FD&C) Act.

Biocon has assured investors that they will address these observations within the timeframe stipulated by the USFDA.

What is a Form 483?

A Form 483 is an official document used by the USFDA to communicate its observations of potential violations during a GMP inspection.

It serves as a notification to the inspected firm’s management, highlighting areas where practices or conditions may not meet the established regulatory requirements.

What Happens Next?

Biocon will now initiate a comprehensive process to address the observations outlined in the Form 483.

This will likely involve a detailed investigation of each observation, followed by the implementation of corrective and preventive actions (CAPAs) to ensure compliance with USFDA regulations.

Biocon will then submit a written response to the USFDA, outlining the specific actions taken to address each observation.

Importance of GMP Compliance for Biocon

Maintaining GMP compliance is crucial for Biocon’s continued success in the global pharmaceutical market.

These regulations ensure the quality, safety, and efficacy of their API products.

A successful resolution of the observations outlined in the Form 483 will minimize potential disruptions to Biocon’s manufacturing operations and ensure continued trust from their customers and regulatory bodies.

Investors Advised to Monitor the Situation

While receiving a Form 483 is not uncommon during routine inspections, it’s important for investors to stay informed about the developments.

Biocon is expected to provide further updates on their progress in addressing the USFDA observations.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news